MDMA — Pharmala Biotech Holdings Share News
0.000.00%
Last trade - 00:00- CA$17.47m
- CA$17.23m
- CA$0.61m
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders
Brief: Pharmala Delivers MDMA To Merhavim Mental Health Centre Clinical Trial In Exchange For Full Data License
Brief: Pharmala Issues Q2 Financial Statements
Brief: PharmAla Closes Private Placement and Concurrent Debt Settlement
Brief: PharmAla Announces Private Placement And Concurrent Debt Settlement
Brief: Pharmala Biotech And Filament Health Announce Release Of Second Batch Of Gmp Mdma Capsules
Australia's Vitura Health up on JV with Canada biotech co
Brief: Vitura Health And Pharmala Biotech Establish A 50:50 Joint Venture, Called Cortexa
Brief: Pharmala Biotech To Supply Clinical Psychedelic Lab At Monash University Clinical Trial With Laneo Mdma
Brief: PharmAla Submits Pre-IND Dossier For Novel MDMA Analog To FDA
Brief: Pharmala Appoints Dr. Leah Mayo To Scientific Advisory Board
Brief: PharmAla Biotech To Supply University Of California Clinical Trial With Laneo™ Mdma
Brief: PharmAla Biotech To Supply University Of Sydney Clinical Trial With LaNeo MDMA
Brief: PharmAla Biotech Adds David Purcell As Director Of Sales